CALGARY, Oct. 18 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular diseases, today announced that it has achieved
the commercial threshold of apolipoprotein AI (native Apo AI) accumulation in
safflower seed. While SemBioSys confirmed in a press release dated August 22,
2007 that it had achieved commercially viable levels of the Apo AI(Milano)
variant, it has now also attained commercial levels of native Apo AI in
safflower.
